Pfizer Inc. ($PFE) Stock Forecast: Down 5.4% Today

What is Pfizer Inc.?

Pfizer (PFE) is a leading pharmaceutical company known for its innovative drugs and vaccines. The stock market today experienced a strong bearish movement.

Why is Pfizer Inc. going down?

PFE stock is down 5.4% on Apr 4, 2025 14:46

• Despite positive news about expanding the use of its RSV vaccine in the EU and receiving endorsements for its blood cancer combo therapy in the UK, Pfizer (PFE) faced a bearish movement.
• The decline in PFE's stock could be attributed to the overall uncertainty in the pharmaceutical sector due to proposed tariffs on pharma imports, impacting various drug stocks including PFE, MRK, ABBV, and LLY.
• Investors are comparing Pfizer (PFE) with Johnson & Johnson (JNJ) and assessing which drug giant presents a better investment opportunity, leading to a shift in market sentiment towards JNJ over PFE.
• Although Pfizer (PFE) expects improvements in sales and profits in the future, the current market reaction suggests that investors are cautious about the company's performance in the near term, contributing to the bearish movement in its stock price.

PFE Price Chart

PFE Technical Analysis

PFE News

JNJ vs. PFE: Which Drug Giant is a Better Buy Now?

Both JNJ & PFE expect their sales and profits to improve in 2025.

https://www.zacks.com/stock/news/2439812/jnj-vs-pfe-which-drug-giant-is-a-better-buy-now

Pfizer ( PFE ) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

https://www.zacks.com/stock/news/2439358/pfizer-pfe-increases-yet-falls-behind-market-what-investors-need-to-know

UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients - Pfizer ( NYSE:PFE )

NICE's recommendation covers about 800 patients annually with stage 3 or 4 Hodgkin lymphoma. ECHELON-1 trial showed brentuximab combo therapy significantly improves survival rates. Feel unsure about the market's next move?

https://www.benzinga.com/general/biotech/25/04/44614171/uks-health-agency-endorses-pfizers-blood-cancer-combo-therapy-as-first-for-untreated-hodgkin-lymp

PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters

Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.

https://www.zacks.com/stock/news/2438962/pfe-mrk-lly-other-drug-stocks-down-amid-tariff-jitters

PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.

https://www.zacks.com/stock/news/2438778/pfe-secures-eu-nod-for-expanded-use-of-rsv-vaccine-abrysvo

Trending Today

MANTRA ($OM) Crypto Forecast: Down 7.5% Today

NEAR Protocol ($NEAR) Crypto Forecast: Up 5.0% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.1% Today

Memecoin ($MEME) Crypto Forecast: Up 15.5% Today

Render ($RENDER) Crypto Forecast: Up 5.2% Today

Kusama ($KSM) Crypto Forecast: Up 5.3% Today

Bonk ($BONK) Crypto Forecast: Up 5.5% Today

Solana ($SOL) Crypto Forecast: Up 5.3% Today

Immutable ($IMX) Crypto Forecast: Up 7.9% Today

Bittensor ($TAO) Crypto Forecast: Up 7.7% Today

Pfizer Inc. Price History

04.03.2025 - PFE Stock was down 5.4%

• Despite positive news about expanding the use of its RSV vaccine in the EU and receiving endorsements for its blood cancer combo therapy in the UK, Pfizer (PFE) faced a bearish movement.
• The decline in PFE's stock could be attributed to the overall uncertainty in the pharmaceutical sector due to proposed tariffs on pharma imports, impacting various drug stocks including PFE, MRK, ABBV, and LLY.
• Investors are comparing Pfizer (PFE) with Johnson & Johnson (JNJ) and assessing which drug giant presents a better investment opportunity, leading to a shift in market sentiment towards JNJ over PFE.
• Although Pfizer (PFE) expects improvements in sales and profits in the future, the current market reaction suggests that investors are cautious about the company's performance in the near term, contributing to the bearish movement in its stock price.

15.10.2024 - PFE Stock was down 7.4%

• Pfizer's stock faced significant downward pressure due to concerns surrounding the appointment of a vaccine skeptic to lead the HHS by President-elect Donald Trump.
• This development led to a bearish response in Pfizer's stock price and also impacted other vaccine makers like Moderna, Novavax, and BioNTech.
• Despite the recent decline, there may be an opportunity for investors to consider purchasing Pfizer's stock as it is currently oversold, with analysts increasing earnings estimates, suggesting a potential reversal in the stock's trend soon.

15.10.2024 - PFE Stock was down 6.3%

• Today, Pfizer's stock showed a decline.
• The appointment of a vaccine skeptic, Robert F. Kennedy Jr., by President-elect Donald Trump to lead the HHS has created doubt and uncertainty in the market.
• While Pfizer has seen success in oncology treatments, the focus on vaccine-related news and the prevailing sentiment in the healthcare industry have had a negative impact on the stock.
• Despite indications of bullish options trading towards Pfizer from well-resourced investors, suggesting a possible future upturn, the current market trend remains bearish due to external factors.

29.09.2024 - PFE Stock was down 1.9%

• Despite reporting strong Q3 earnings and revenue beats, the market movement may have been influenced by profit-taking behavior from investors after a period of heightened demand for its COVID products.
• The heightened demand for Paxlovid and expectations of $10 billion in 2024 revenue from COVID products may have already been priced into the stock, leading to a sell-off post-earnings.
• The ongoing proxy battle with activist investor Starboard Value could have added uncertainty and pressure on the stock, contributing to the bearish movement.
• Investors might be closely monitoring Pfizer's non-COVID drug performance and the impact of new and acquired products on the company's future revenue growth, which could influence future market sentiment.

24.01.2025 - PFE Stock was up 0.2%

• The bullish movement in Pfizer's stock today can be attributed to several factors:
• The discovery of a new coronavirus in China has led to a rise in vaccine stocks, including Pfizer, as investors anticipate increased demand for vaccines in response to potential outbreaks.
• Pfizer's decision to discontinue the hemophilia gene therapy Beqvez, which saw low adoption rates, could be viewed positively by investors as the company shifts its focus to more promising products like Hympavzi.
• Despite ongoing investigations into Pfizer's Board of Directors for potential breaches of fiduciary duties, the market seems to be focusing more on the company's product developments and potential for growth in the healthcare sector.

09.08.2024 - PFE Stock was up 2.3%

• The surge in Pfizer's stock was attributed to positive developments in the pharmaceutical industry, particularly related to competitors and collaborations, which increased investor confidence.
• Moderna's recent positive CHMP opinion and approval for an updated COVID-19 vaccine likely contributed to sector-wide optimism and benefitted Pfizer.
• Vaxcyte's vaccine study results, showing strong immune responses and reaching a record high, created a positive sentiment for vaccine-related companies like Pfizer.
• Pfizer's strategic clinical partnership with Acepodia to expedite development in autoimmune diseases indicated potential growth opportunities, driving up the stock price further.

04.01.2025 - PFE Stock was down 2.5%

• Pfizer surpassed earnings and revenue projections in Q4, demonstrating robust performance in its Seagen and COVID-19 product lines. However, despite this, the stock witnessed a downward trend.
• Concerns regarding Pfizer's sustainability of growth momentum, particularly in meeting financial expectations, could have prompted the market's negative response.
• Investors may have anticipated even stronger results from Pfizer, resulting in profit-taking and a temporary decline in stock value.
• The market movement may also be influenced by broader industry trends or sector-specific factors impacting pharmaceutical companies.

09.09.2024 - PFE Stock was up 2.9%

• Pfizer's stock experienced a strong bullish movement today.
• The stock rose after receiving a $1 billion investment from activist investor Starboard Value, leading to optimism about a potential turnaround for the company.
• Additionally, Pfizer won a court battle in London, which may have boosted investor confidence in the company's future prospects.
• The news of the investment and legal victory likely contributed to the bullish market movement for Pfizer today.

08.00.2025 - PFE Stock was down 2.4%

• Pfizer (PFE) experienced a strong bearish movement today.
• The market might have reacted negatively to specific news related to Pfizer, such as disappointing clinical trial results or regulatory setbacks.
• Investors could be concerned about potential challenges in Pfizer's pipeline or competitive pressures impacting its revenue outlook.
• It's essential for traders to stay updated on Pfizer's latest developments and industry trends to make informed investment decisions in the pharmaceutical sector.

11.06.2024 - PFE Stock was up 1.3%

• Pfizer's bullish movement today can be attributed to the positive news regarding the advancement of its once-daily weight-loss pill, danuglipron, which shows promise in the ongoing Phase 1 study. This development indicates potential future revenue streams and market expansion for the company.
• The company's decision to move forward with the once-daily version of the weight-loss pill, despite previous setbacks, demonstrates Pfizer's commitment to innovation and addressing market needs.
• The search for a new Chief Scientific Officer following Dr. Mikael Dolsten's departure may have initially caused some uncertainty in the market, but the overall positive news regarding product development likely overshadowed this aspect, contributing to the bullish movement in the stock.

30.06.2024 - PFE Stock was down 2.0%

• Despite Pfizer delivering robust earnings with revenue exceeding expectations and achieving its first revenue growth since the COVID peak in 2022, the stock encountered a bearish trend.
• The market's response may have been influenced by the substantial decrease in reported net income, showing a 98% year-over-year decline.
• Investors could be expressing worries about Pfizer's dependency on COVID-related products, as the company faces a sharp revenue decline in that particular segment.
• Despite the overall positive market sentiment and Pfizer's increased annual profit forecast driven by strong sales of cancer and heart drugs, the negative impact of the severe net income decline on the stock price was not overcome.

30.06.2024 - PFE Stock was up 1.4%

• Pfizer's recent market movement is linked to its first sales growth since the onset of the pandemic, especially in the field of cancer treatment, demonstrating its capacity to adapt and innovate in evolving market conditions.
• Strong Q2 results, surpassing earnings per share and revenue projections, likely bolstered investor trust in the company's performance and future potential.
• Amid declines in tech stocks and surges in financials and energy stocks, Pfizer's steadfastness and emphasis on areas like cancer treatment resonated with investors, sparking increased interest and a bullish trend for the stock.